Discussion and Conclusion:Anemarrhena asphodeloides contains multiple active ingredients, which may exert therapeutic effects on osteoporosis by regulating targets such as AKR1C1, AKR1C2, ABCC1, SMO, and AKT1 and key signaling pathways like PI3K‐Akt and VEGF, thereby providing theoretical support for the clinical use of Anemarrhena asphodeloides in the treatment of osteoporosis. Here, VEGFA is linked to osteoporosis.